$IMUX

Immunic, Inc. (IMUX) presented new data on vidofludimus calcium at MSToronto2026. Phase 2 CALLIPER trial data showed durable disability outcomes and consistent safety. Preclinical data suggested neuroprotective effects. Exploratory analyses linked reduced EBV-specific T-cell signatures to improved cognitive performance. A novel disability measure suggested overall benefits in progressive MS patients. The company plans to initiate a Phase 3 program in progressive MS later this year.

Immunic (IMUX) will present new data on vidofludimus calcium (IMU-838) at MSToronto2026. Four abstracts cover long-term disability outcomes, EBV-related immune activity, cognition, and novel disability measurement. Phase 2 CALLIPER trial data show favorable disability outcomes with continuous treatment. Immunic aims to showcase vidofludimus calcium's potential in multiple sclerosis.

Immunic (IMUX) granted director Robert Thorvald Nagel 25,370 stock options at $10.12 per share. The options vest monthly over one year and expire in 2036. The economic benefits will be transferred to BVF Partners L.P.

Immunic, Inc. (IMUX) announced Dr. Duane Nash's resignation from its Board of Directors, reducing the board size to nine members. The company stated the resignation was not due to any disagreement. The change does not indicate any strategic, operational, or financial disruption, according to the filing.

IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Resignation of Director On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (

Immunic (IMUX) held an RMS R&D Day webinar on Sept. 9, 2026, presenting its vidofludimus calcium development plans. The company shared forward-looking statements on clinical development and potential phase 3 progression. Immunic cautioned about risks including trial timing and regulatory outcomes.

Immunic Inc. (IMUX) announced a private placement deal that could raise up to $400 million, with $200 million upfront. The funds will support clinical studies, operations, and future product launches. The stock surged 33% in premarket trading. The company plans to transition to a commercial-stage company and expects funds to last through 2027.

Immunic, Inc. (IMUX) will host a virtual R&D day on September 9, 2026, to discuss its Phase 3 ENSURE trials for vidofludimus calcium, an oral therapy for relapsing multiple sclerosis. The company expects top-line data by the end of 2026. Key opinion leaders will share insights on MS treatment and unmet medical needs.

Analysts reiterated Buy ratings on Immunic (IMUX) with a $29 target, Incyte (INCY) with a $150 target, and Eli Lilly (LLY) with a $1600 target. Consensus targets suggest 167.5%, 6.6%, and 19.1% upside respectively.

Solis Minerals began diamond drilling at its Cinto Copper Project in Peru, targeting high-priority copper zones. First Phosphate reported strong shareholder support and growth in its registered base. Blockmate Ventures submitted a zoning application for its Wyoming AI data centre. 374Water will showcase its waste destruction technology at WEFTEC 2026. Immunic Inc appointed a new chief data and digital officer. TNR Gold faces a dissident shareholder campaign ahead of its annual meeting.